A Bladder Clinic for 13-Year-Olds Is What Ketamine's Growth Curve Actually Looks Like

Alder Hey Children’s Hospital in Liverpool opened the UK’s first ketamine-induced uropathy clinic for under-16s in May 2025, on the assumption that it would see a trickle. It has seen more than 100 referrals. Researchers who analyzed the first 60 patients found an average age of 14 — some as young as 13 — and a pattern that should stop any provider mid-sentence: about 72% were girls, about 72% came from the most deprived neighborhoods in their area, 27% had autism or ADHD, 20% had prior involvement with the care system, and roughly 72% had a documented history of emotional trauma, according to the study reported by News-Medical.net from the peer-reviewed paper in Archives of Disease in Childhood.

Ketamine did not pick these kids at random, and neither does most of what we call “dissociative” drug harm.

That’s the sentence worth sitting with, because “dissociative” gets talked about in the abstract — a pharmacological category, a receptor mechanism — when the data keeps showing something much more specific: it lands hardest on kids who are already dissociating from something else. The average patient in the Alder Hey cohort had used ketamine for one to two years before being referred, alongside other drugs in half the cases, alcohol in 27%, and vapes in 48%. Researchers behind the study told ITV News that services need to be trauma-informed and co-designed with the young people who use them — not bolted on after the damage is diagnosed.

What ketamine actually does to a bladder, explained once, plainly

Ketamine is an anesthetic — it was developed for surgery, and it still is one, used safely every day in operating rooms and, in a different form and dose, as the FDA-approved depression treatment esketamine (brand name Spravato). What’s different with sustained recreational use is dose and duration: repeated exposure over months or years appears to directly irritate and scar bladder tissue, a condition doctors call ketamine-induced uropathy or, more bluntly, “ketamine bladder.” Patients describe it as a constant, urgent need to urinate, often with blood and searing pain — not a side effect that shows up once and fades, but one that gets worse with continued use and can, in severe cases, require surgery to remove the bladder entirely.

It isn’t only the bladder. In the largest study of its kind, 274 people with a ketamine use disorder were surveyed by researchers at the University of Exeter and UCL, and 56% reported “K-cramps” — severe, occasionally disabling cramping across multiple organs — nearly double an earlier estimate that put the figure at one in three. Of those with K-cramps, 60% also reported bladder or nasal damage. And here’s the detail that turns a physical symptom into a dependence mechanism: people in the study described the cramping pain itself as something ketamine relieves — meaning the drug becomes both the cause of the pain and the only thing that makes it stop. That is not a metaphor for addiction. That is addiction’s actual architecture, described by the people living inside it.

The loop, and what’s happening in the brain during it

If you’ve ever heard someone describe craving as “not really wanting the drug, just needing the feeling to stop,” the K-cramps pattern is that experience with a physical trigger attached. Researchers are starting to find the biology underneath it: a study using machine learning on brain-imaging data from 94 people with ketamine dependence found measurable differences in cortical thickness and subcortical brain volume that predicted how intensely someone reported craving — an early attempt to locate craving’s neuroanatomical fingerprint rather than treat it as purely subjective. Paired with the Exeter findings, the emerging picture is a loop with two engines instead of one: a psychological craving state and a physical pain state, each capable of driving the other, which is part of why “just stop” is such a useless thing to say to someone in it.

We’ve watched a “safe in the clinic, dangerous on the street” story before, with a chemical cousin of this exact drug. PCP — a close relative of ketamine in the same arylcyclohexylamine family — was developed in the 1950s as a surgical anesthetic and pulled from human medical use by 1965 after patients experienced severe, unpredictable psychiatric reactions coming out of anesthesia. It didn’t disappear; it moved to the street as “angel dust” through the 1970s, and the harm concentrated, as it so often does, among people with the least stability and the fewest resources to absorb it. Ketamine’s medical value is real and its psychiatric applications are more rigorously studied than PCP’s ever were — but the migration pattern, clinic to street to the most vulnerable users, is not a new shape. It’s the oldest one in this drug class.

We’ve watched a “safe in the clinic, dangerous on the street” story before, with a chemical cousin of this exact drug.

The industry racing ahead of the regulation

We covered ketamine’s regulatory reckoning as an industry story earlier this month; today’s data is the patient-side half of that same story. Part of why ketamine is everywhere right now is supply: the number of US ketamine clinics grew from fewer than 100 in 2015 to more than 1,500 by 2024, a roughly $3.4 billion market, almost all of it operating off-label, since ketamine itself — unlike esketamine — has no FDA approval for psychiatric use and no Risk Evaluation and Mitigation Strategy requirement, according to Pharmaceutical Executive’s analysis of the sector. The DEA has already suspended at least one telehealth prescriber’s controlled-substance registration and pursued a federal fraud case against physicians accused of absentee medical oversight. None of that regulatory activity touches the population showing up at Alder Hey, who aren’t ketamine-clinic patients — they’re kids getting the drug recreationally, the same way alcohol and nicotine reach them, through peer networks and unregulated sale.

The clinical story next door tells a version of the same thing: nitrous oxide poisoning deaths in the US rose 578% between 2010 and 2023, from 23 deaths to 156 annually, driven largely by recreational use among adolescents and young adults as canisters — sold as “Galaxy Gas” and similar brands — became cheaper and more available. Congress is now moving on it: the House Energy and Commerce Committee voted 36-0 in September to advance a bill banning direct-to-consumer retail sale. It’s the same regulatory lag playing out on a different dissociative, in a different chemical family, with the same age group absorbing the cost while the policy catches up.

For more on the full dissociatives class — and the science and medicine reporting we do across every substance we track — the throughline is the same one above. For a case manager or pediatrician, the actionable version of all this is simple: if you’re screening a teenager who has other risk factors on the list above — trauma history, care-system involvement, neurodivergence, economic deprivation — ketamine and nitrous oxide deserve a direct question, not a general “any drug use?” checkbox. The Alder Hey data didn’t find dissociative harm distributed evenly across British teenagers. It found it concentrated in the kids the system was already failing before ketamine ever entered the picture, and that’s the number that should be driving where we put the next clinic, not just the last one.